Gordon Shore

Affiliation : Université McGill
Organization : Rosalind and Morris Goodman Cancer Centre
E-mail : gordon.shore@mcgill.ca

About Gordon Shore

Gordon Shore received his PhD in Plant Biochemistry from McGill University in 1974. Upon joining Jam Tata’s Laboratory of Developmental Biochemistry at the National Institute for Medical Research (Mill Hill) in the U.K., he turned his attention as a post-doc to studies on the cross-talk between the endoplasmic recitulum (ER) and mitochondria. This led to an interest in mitochondrial protein biogenesis, in particular the regulation of protein insertion and orientation in the outer membrane, and mechanisms that sort proteins between the outer and inner membranes. This work was conducted primarily in the department of Biochemistry at McGill, where Gordon Shore became professor of Biochemistry in 1986. In the early 90’s, his interests shifted to cancer and Bcl-2, with special attention on p53 and Bcl-2 regulated ER pathways. Together with his colleague Phil Branton, he founded Gemin X Pharmaceuticals inc. in 1998 with the goal to translate the understanding of these de-regulated pathways in cancer into therapeutic opportunities. Professor Shore is currently the Chief Scientific Officer, a member of the Board of Directors, and was interim CEO (2007-2008) of Gemin X, while retaining his professorship and basic research laboratory at McGill.

Ongoing competitions